United States: The Trump Administration Drug Importation Action Plan

As part of the Trump Administration's Blueprint to Lower Drug Prices, on July 31, 2019 the Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) released a Safe Importation Action Plan (Action Plan) outlining the Administration's intention to develop two pathways for the legal importation of certain drugs. The Action Plan, however, provides only a broad overview of the Administration's proposals, and there are many details which will need to be clarified and administrative processes to navigate before the proposals can be implemented. 

Background on Proposals to Allow the Importation of Drugs into the US

For decades, various administrations have considered ways to access cheaper drugs by importing medications from foreign countries via the potential implementation of amendments to existing law prohibiting importation by entities other than the drug manufacturer. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 amended FDCA § 804 to permit the importation of drugs from Canada in certain limited circumstances. The Act only allowed for the importation of Canadian drugs if the Secretary of HHS certified that such imports posed no additional risk to public health and also resulted in a significant cost reduction to American consumers. However, since the passage of the Act, HHS has not approved drug importation plans due to safety and other concerns. Since 2003, dozens of bills have been introduced in Congress to provide a legal pathway for the importation of drugs from Canada and other industrialized countries. In 2019 alone, several bills—including most notably, the Affordable and Safe Prescription Drug Importation Act (S. 97, H.R. 447) and the Safe and Affordable Drugs from Canada Act (S. 61, H.R. 478)—have been introduced in both the House and Senate. While many of these bills include similar provisions, they often differ in the details of what countries are included, what entities in the US are authorized to import, which types of drugs may be imported, and whether the bills include restrictions on drug manufacturers from retaliating against suppliers of foreign drugs or otherwise contracting around the obligations set forth in the legislation.

In addition to proposed federal legislation, a growing number of states—such as Vermont, Maine, Florida and Colorado—have recently passed laws legalizing the importation of foreign drugs. Many of these state laws rely on federal action and the importation authority granted to the Secretary of HHS under FDCA § 804, and are adapted from model legislation developed by the National Academy for State Health Policy.

In the past, such proposals have largely been met with resistance by the FDA. In 2017, four former FDA commissioners signed a joint letter to Members of Congress warning that the importation of foreign drugs was "likely to harm patients and consumers." Indeed, HHS Secretary Alex Azar said as recently as May 2018 that drug importation from Canada was a "gimmick." In contrast, the Administration's Action Plan was met with approval and support by both Secretary Azar and FDA Commissioner Sharpless, who tweeted that the "FDA supports @POTUS and @SecAzar's efforts to bring down drug prices" and that "The Safe Importation Action Plan is the result of the hard work by dedicated FDA staff in close collaboration with HHS & the White House."

Summary of the Action Plan

The Action Plan broadly outlines two proposed pathways through which HHS and FDA will allow for the importation of certain drugs originally intended for non-US markets. Notably, both pathways rely on parties other than the federal government—such as states, wholesalers, pharmacists, and manufacturers—to demonstrate that eligible drugs can be imported into the US safely and with the required cost savings.

  • Pathway 1: State-Based Demonstrations: The Administration proposes to release a Notice of Proposed Rulemaking (NPRM) under the authority granted in FDCA § 804. The NPRM will authorize states, wholesalers or pharmacists to submit demonstration project proposals to HHS which outline a plan to import certain types of drugs from Canada. While the actual language of the NPRM was not released, the Action Plan provided a general outline of the NPRM's intended content:
    • Demonstrations: Demonstrations will be time-limited and require regular reporting to ensure safety and cost conditions are met. Applications from states need to propose an arrangement with a wholesaler or pharmacist that meets the conditions of the NPRM. Proposed demonstrations must discuss how the program will comply with track and trace requirements, FDCA labeling requirements, and importation entry requirements, among others.
    • Eligible Drugs: The NPRM will exclude controlled substances, biological products, infused drugs, intravenous drugs, drugs inhaled during surgery, drugs with REMS, and certain parenteral drugs. Eligible prescription drugs must:
      • be authorized for sale in Canada;
      • be versions of FDA-approved medications;
      • contain only active pharmaceutical ingredients manufactured at facilities that also manufacture such ingredients for the FDA-approved version of the medication;
      • be formulated using processes, specifications, and facilities in accordance with the approved new drug application for the FDA-approved version; and
      • be labeled to indicate that they were originally intended for distribution in Canada.
    • Cost Requirements: The NPRM will explain requirements for demonstrating that the imported drugs result in a significant cost reduction to American consumers.
  • Pathway 2: Manufacturer Importation: FDA will allow manufacturers of FDA-approved drugs the ability to import foreign versions of those drugs for sale in the US if the manufacturer can establish that the foreign version is the same as the American version (such as through manufacturing records). Under this pathway, FDA would allow approved drugs to use a different NDC number than their American version, which the Action Plan suggests will allow the manufacturer to introduce the product at a lower price. The Action Plan notes that this pathway relies on existing supply chain safeguards and requirements, as the drugs would be authorized for importation through conventional channels, but offers no further details on how manufacturers would comply with such safeguards.

Outstanding Questions and Concerns

The Action Plan provides a limited overview of the Administration's proposed plans, and many important issues and questions remain unclear or unanswered. For instance:

  • On July 19, 2019, Secretary Azar directed the FDA to establish a working group on drug importation in order to address price increases. HHS noted that "[t]his working group will examine the potential to promote competition for drugs that are off-patent or off-exclusivity and produced by one manufacturer" and that such proposals "stand[] in contrast to proposals to import a broader range of drugs[.]" The relationship between the working group and the Action Plan is not clear, nor is there clarity in how the mandate to promote competition for off-patent or off-exclusivity drugs will coexist with the proposals in the Action Plan.
  • The specific safety and supply chain safeguards required under either of the Action Plan's pathways are left to the discretion of the Administration through future agency actions. It is not yet clear how such safeguards would be maintained, how stakeholders would be responsible for establishing and demonstrating compliance, or whether the costs of compliance would negate or seriously diminish any cost savings.
  • The Action Plan does not provide a timeline for the release of the NPRM or the implementation of the second pathway. It is not clear when additional steps by the Administration may be taken on either pathway.
  • The NPRM requires compliance with the statutory requirements of FDCA § 804, including a demonstration that a drug importation plan will lead to significant cost savings by American consumers. It is unclear how such savings will actually be achieved given potential supply limitations, etc.
  • A number of states are in the process of submitting foreign drug importation proposals to HHS for review based on HHS' current statutory authority under FDCA § 804. It is not yet clear how any such submitted proposals will be impacted or otherwise interact with the final language of the NPRM. Similarly, it is not clear how states may respond if any existing state-level legislation ultimately conflicts with the requirements set forth in the final language of the NPRM.1
  • Canadian officials have made clear that they do not support US plans to import Canadian drugs, and that they fear such plans could lead to higher costs or drug shortages in Canada. Health Canada noted that the Canadian government is prepared to "take action to ensure Canadians have uninterrupted access to the prescription drugs they need." It is not clear how the Administration proposes to address Canadian resistance to American efforts to import foreign drugs.

In addition to commenting on these proposals as they emerge, stakeholders should evaluate the potential impact of these importation proposals on their distribution chains and current arrangements for the sale of drugs in Canada (and potentially other jurisdictions), product integrity and anti-counterfeiting efforts, and intellectual property rights.  For example, importation provisions prohibit certain manufacturer efforts to restrict importation, but the scope of such restrictions has not been tested.  We will be closely following the further development of the Action Plan, and we will provide updates to this advisory.

*Ira Stup contributed to this Advisory. Mr. Stup is a graduate of the University of Michigan Law School and is employed at Arnold & Porter's Washington, DC office. He is admitted to practice in New York. He is not admitted to the practice of law in Washington, DC.

© Arnold & Porter Kaye Scholer LLP 2019 All Rights Reserved. This Advisory is intended to be a general summary of the law and does not constitute legal advice. You should consult with counsel to determine applicable legal requirements in a specific fact situation.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions